Trial · NCT00976963

Single Dose Monurol for Treatment of Acute Cystitis

NCT00976963, Not applicable, Completed, University of Washington; results first posted 2023-06-05

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Single Dose Monurol for Treatment of Acute Cystitis. Trials, record NCT00976963. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00976963

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Single Dose Monurol for Treatment of Acute Cystitis
NCT number: NCT00976963
Status: Completed
Phases: Not applicable
Enrollment: 300 participants, actual
Lead sponsor: University of Washington
Conditions: Urinary Tract Infection
Interventions: TMP/SMX, Fosfomycin
First posted: 2009-09-15
Last updated: 2023-06-05
Results first posted: 2023-06-05
Limitations and caveats: The clinicians and participants were not blinded as to the assigned intervention.

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants Who Were Cured	28-30 days post therapy	Cure as defined by no further treatment for subsequent or unresolved symptoms, by modified ITT approach.

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants Who Were Cured	28-30 days post therapy		Participants	COUNT_OF_PARTICIPANTS

Source ClinicalTrials.gov

Results by group2

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Number of Participants Who Were Cured	TMP/SMX		120		Participants
Number of Participants Who Were Cured	Fosfomycin		130		Participants

Source ClinicalTrials.gov

Participant flow8

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	TMP/SMX	150
Overall Study	STARTED	Fosfomycin	150
Overall Study	Treated With Assigned Intervention	TMP/SMX	146
Overall Study	Treated With Assigned Intervention	Fosfomycin	150
Overall Study	COMPLETED	TMP/SMX	146
Overall Study	COMPLETED	Fosfomycin	150
Overall Study	NOT COMPLETED	TMP/SMX	4
Overall Study	NOT COMPLETED	Fosfomycin	0

Source ClinicalTrials.gov

Adverse events12

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Nausea	Gastrointestinal disorders	TMP/SMX	22	143
other	Nausea	Gastrointestinal disorders	Fosfomycin	3	145
other	Loose stools	Gastrointestinal disorders	TMP/SMX	7	143
other	Loose stools	Gastrointestinal disorders	Fosfomycin	28	145
other	Abdominal discomfort	Gastrointestinal disorders	TMP/SMX	10	143
other	Abdominal discomfort	Gastrointestinal disorders	Fosfomycin	12	145
other	Headache	General disorders	TMP/SMX	11	143
other	Headache	General disorders	Fosfomycin	3	145
other	Dizziness	General disorders	TMP/SMX	7	143
other	Dizziness	General disorders	Fosfomycin	3	145

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	TMP/SMX	0	150
Total, all-cause mortality	Fosfomycin	0	150
Total, other adverse events	TMP/SMX	46	143
Total, other adverse events	Fosfomycin	43	145
Total, serious adverse events	TMP/SMX	0	150
Total, serious adverse events	Fosfomycin	0	150

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons3

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
TMP/SMX vs Fosfomycin: Number of Participants Who Were Cured	Trial comparisons
TMP/SMX vs Fosfomycin: deaths from any cause	Trial comparisons
TMP/SMX vs Fosfomycin: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00976963

GET https://conductscience.org/api/trials/v1/NCT00976963/registered

API reference For AI assistants